Search hospitals
>
California
>
Palo Alto
Stanford Cancer Institute Palo Alto
Claim this profile
Palo Alto, California 94304
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Lymphoma
Conducts research for Pancreatic Cancer
556 reported clinical trials
67 medical researchers
Summary
Stanford Cancer Institute Palo Alto is a medical facility located in Palo Alto, California. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Lymphoma, Pancreatic Cancer and other specialties. Stanford Cancer Institute Palo Alto is involved with conducting 556 clinical trials across 590 conditions. There are 67 research doctors associated with this hospital, such as Andrei Iagaru, MD, Robert Lowsky, MD, Christopher Chen, and Lori Muffly, MD.
Area of expertise
Breast Cancer
Stanford Cancer Institute Palo Alto has run 77 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Stanford Cancer Institute Palo Alto has run 71 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Andrei Iagaru, MD
Stanford University
1 year of reported clinical research
Robert Lowsky, MD
Stanford University
2 years of reported clinical research
Christopher Chen
Stanford Cancer Institute
2 years of reported clinical research
Lori Muffly, MD
Stanford Cancer Institute
3 years of reported clinical research
Clinical Trials running at Stanford Cancer Institute Palo Alto
Lung Cancer
Breast Cancer
Cancer
Skin Cancer
Ovarian Cancer
Prostate Cancer
Breast cancer
Uterine Cancer
Chronic Lymphocytic Leukemia
Bladder Cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
Radiation Therapy
for Brain Metastasis
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting
2 awards
Phase 3
12 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Stanford Cancer Institute Palo Alto?
Stanford Cancer Institute Palo Alto is a medical facility located in Palo Alto, California. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Lymphoma, Pancreatic Cancer and other specialties. Stanford Cancer Institute Palo Alto is involved with conducting 556 clinical trials across 590 conditions. There are 67 research doctors associated with this hospital, such as Andrei Iagaru, MD, Robert Lowsky, MD, Christopher Chen, and Lori Muffly, MD.
Where is Stanford Cancer Institute Palo Alto located?
**Directions to Stanford Cancer Institute Palo Alto:** - **By Car:** Exit at Page Mill Road and proceed east. Turn right onto Deer Creek Road, then left at Arastradero Road. The hospital is located at 1050 Arastradero Road. - **By Shuttle:** Utilize the Marguerite Shuttle Line X and Line Y for service between the Palo Alto Transit Center and the School of Medicine.
Who should I call to ask about financial aid or insurance network?
**Stanford Cancer Institute Palo Alto - Financial and Patient Care Contacts** - **Financial Assistance and Insurance Inquiries:** Contact the Financial Counseling department at **844-498-2900**. Available Monday-Friday, 8 a.m.-5 p.m. - **Patient Care Contacts:** For specific patient care, reach out to the Stanford Clinical Cancer Center at **650.498.6000**.
What insurance does Stanford Cancer Institute Palo Alto accept?
The Stanford Cancer Institute Palo Alto accepts most major commercial health plans, including HMO, PPO, EPO, and POS plans, covering hospital and specialist physician services for cancer care. However, the ability to choose a Stanford Health Care physician as a primary care physician varies by plan; for example, HMO plan holders cannot select a Stanford Health Care physician as their primary care physician but can be referred for cancer care services. For the most accurate information regarding coverage, contact your employer's benefit department or your health plan, and to verify if Stanford Health Care is in-network with your specific plan, call the Anthem member services department with Stanford Health Care's Tax ID number (77-0465765).
What awards or recognition has Stanford Cancer Institute Palo Alto received?
The Stanford Cancer Institute in Palo Alto, California, is recognized as a Comprehensive Cancer Center by the National Cancer Institute. This prestigious designation highlights the institute's dedication to excellence in cancer research, encompassing basic, translational, clinical, and population-based studies. With over 450 members from diverse disciplines, the institute aims to translate research advances into improved treatments, supporting activities across Stanford University, Stanford Health Care, and Lucile Packard Children’s Hospital Stanford.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.